Clinical Study
Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre Experience
Table 4
Baseline and end-treatment SUV max values recorder for all patients in the main lesion assessed by 68Ga-peptide PET/CT tabulated on the basis of patients’ functional response.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
çData from the 4 patients in which PD was assessed using 68Ga-peptide PET/CT. |